NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...
C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...
Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...
Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...
Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...
Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine...
FDA Alert: Chinese Syringe Maker Jiangsu Shenli Initiates Voluntary Recall
This week, the US Food and Drug Administration (FDA) provided a status report on its...
Porton Pharma Solutions Invests €50 Million in Slovenian R&D Expansion
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has inaugurated a new...
MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First
Merck KGaA (NYSE: MRK)’s US life sciences division, MilliporeSigma, has been at the center of...
AstraZeneca Sets Sights on $80 Billion Revenue Target and 20 New Molecular Entities by 2030
At its recent investor day, AstraZeneca plc (NASDAQ: AZN), a prominent UK pharmaceutical company, articulated...
Jiangsu Hengrui’s Fluzoparib Gains NMPA Approval as Maintenance Therapy for Ovarian Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Sichuan Biokin’s BL-B01D1 Advances to Phase III for HR+/HER2- Breast Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced the enrollment...
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic...
Alphamab Oncology’s JSKN016 Begins Phase I Clinical Trial for Solid Tumor Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company, has announced that the first patient has been...
Jacobio Pharma’s Gecirasib Gets Priority Review for NSCLC Treatment by China’s NMPA
Jacobio Pharma (HKG: 1167), a leading biopharmaceutical company based in China, has announced that its...
Shanghai Fosun Pharma’s FCN-159 Receives Priority Review for Pediatric Neurofibromatosis Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has achieved a significant milestone...
Asymchem Laboratories Enters European Market with Pfizer’s UK API Plant and R&D Lab Purchase
Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading China-based Contract Development and Manufacturing Organization...
China Invalidates Heart Failure Patent for Dapagliflozin, Maintains Protection for Kidney Disease Use
The China National Intellectual Property Administration (CNIPA) has announced a pivotal decision concerning the patent...
Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...